Ocifisertib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Ocifisertib
- DrugBank Accession Number
- DB18746
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 534.66
Monoisotopic: 534.263090971 - Chemical Formula
- C33H34N4O3
- Synonyms
- (1R,2S)-2-[3-[(1E)-2-[4-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5′-methoxyspiro[cyclopropane-1,3′-[3H]indol]-2′(1′H)-one
- (1R,2S)-2-{3-[(E)-2-(4-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}phenyl)ethen-1-yl]-1Hindazol-6-yl}-5'-methoxyspiro[cyclopropane-1,3'-indol]-2'(1'H)-one
- Cfi-400945 free base
- Spiro(cyclopropane-1,3'-(3h)indol)-2'(1'h)-one, 2-(3-((1e)-2-(4-(((2r,6s)-2,6-dimethyl-4-morpholinyl)methyl)phenyl)ethenyl)-1h-indazol-6-yl)-5'-methoxy-, (1r,2s)-
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Ocifisertib fumarate 09OB3E5QTD 1616420-30-4 AQCDFVLWUWJREO-WQVJSASDSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TL1UD860AA
- CAS number
- 1338806-73-7
- InChI Key
- DADASRPKWOGKCU-FVTQAUBDSA-N
- InChI
- InChI=1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m1/s1
- IUPAC Name
- SMILES
- COC1=CC=C2NC(=O)[C@@]3(C[C@H]3C3=CC=C4C(NN=C4\C=C\C4=CC=C(CN5C[C@H](C)O[C@H](C)C5)C=C4)=C3)C2=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 34979947
- ChEMBL
- CHEMBL3408947
- ZINC
- ZINC000145048061
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Breast Cancer 2 2 Active Not Recruiting Treatment Prostate Cancer 1 1 Active Not Recruiting Treatment Acute Myeloid Leukemia / Myelodysplastic Syndrome / Refractory Cancer / Relapsed Cancer 1 1 Completed Treatment Advanced Malignant Neoplasm 1 1, 2 Recruiting Treatment Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 17, 2024 16:36 / Updated at May 17, 2024 18:09